The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI’s) in non-small cell lung cancer (NSCLC) No ...
The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results